Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0GXWT)

• Drug Name: ABP 654 Drug Info
• Synonyms: Ustekinumab biosimilar

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 3	[1]
Psoriatic arthritis	FA21	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DM0GXWT

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-23 (IL23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ustekinumab	DMHTYK3	Plaque psoriasis	EA90.0	Approved	[3]
Tildrakizumab	DMLW9HG	Plaque psoriasis	EA90.0	Approved	[4]
CNTO-1959	DMPC2QY	Plaque psoriasis	EA90.0	Approved	[5]
Risankizumab	DMM32GT	Plaque psoriasis	EA90.0	Approved	[6]
BI 655066	DMBH4FL	Chronic plaque psoriasis	EA90.0	Phase 3	[7]
MK-3222	DMQBF7O	Hairy cell leukaemia	2A82.2	Phase 3	[8]
Brazikumab	DM4NWPE	Crohn disease	DD70	Phase 3	[9]
CNT0-1959	DMOR8SY	Rheumatoid arthritis	FA20	Phase 2	[5]
mRNA-2752	DMUKBI2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
AMG-139	DMEHOVF	Crohn disease	DD70	Phase 1	[11]

Drug(s) Targeting Interleukine 12 (IL-12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad-RTS-hIL-12	DMCNTFW	Glioblastoma of brain	2A00.00	Phase 2	[12]
GEN-1	DMJN09S	Ovarian cancer	2C73	Phase 2	[13]
Tavokinogene telseplasmid	DMZX0VF	Melanoma	2C30	Phase 2	[14]
MEDI1191	DMD9OVI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
M9241	DMZUM67	Pancreatic cancer	2C10	Phase 1	[16]
YH010	DMA1T66	Aggressive cancer	2A00-2F9Z	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-23 (IL23)	TTC1GLB	IL23A_HUMAN	Not Available	[2]
Interleukine 12 (IL-12)	TTG68FB	IL12A_HUMAN; IL12B_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Amgen
• [3] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
• [8] Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
• [9] Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.
• [10] Clinical pipeline report, company report or official report of Moderna Therapeutics.
• [11] Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.
• [12] Clinical pipeline report, company report or official report of Ziopharm Oncology.
• [13] Clinical pipeline report, company report or official report of Celsion.
• [14] Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
• [15] Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
• [16] Clinical pipeline report, company report or official report of EMD Serono.
• [17] Clinical pipeline report, company report or official report of Biocytogen